Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2
Agnieszka M. Szemiel, Andres Merits, Richard Orton, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 19

Showing 19 citing articles:

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
Bo Meng, Steven A. Kemp, Guido Papa, et al.
Cell Reports (2021) Vol. 35, Iss. 13, pp. 109292-109292
Open Access | Times Cited: 412
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 95
The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape
Darren P. Martin, Steven Weaver, Houryiah Tegally, et al.
medRxiv (2021)
Open Access | Times Cited: 53
Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination
Alexandra Herrmann, Doris Jungnickl, Arne Cordsmeier, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10188-10188
Open Access | Times Cited: 43
Characterisation of B.1.1.7 and Pangolin coronavirus spike provides insights on the evolutionary trajectory of SARS-CoV-2
Samuel J. Dicken, Matthew J Murray, Lucy Thorne, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 41
Sars-Cov-2 and risk of antiviral drug resistance
Antonio Vitiello
Irish Journal of Medical Science (1971 -) (2021) Vol. 191, Iss. 5, pp. 2367-2368
Open Access | Times Cited: 28
Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individual
Maia Kavanagh Williamson, Fergus Hamilton, Stephanie Hutchings, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 24
A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants
Philippe Colson, Christian Devaux, Jean‐Christophe Lagier, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 15, pp. 3276-3276
Open Access | Times Cited: 20
Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic
Huda R. Taha, Nour Keewan, Farah Slati, et al.
Pharmacology (2021) Vol. 106, Iss. 9-10, pp. 462-468
Open Access | Times Cited: 20
Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2
Friedrich Hahn, Sigrun Häge, Alexandra Herrmann, et al.
Pathogens (2021) Vol. 10, Iss. 9, pp. 1076-1076
Open Access | Times Cited: 12
ANALYSIS OF IMMUNE ESCAPE VARIANTS FROM ANTIBODY-BASED THERAPEUTICS AGAINST COVID-19
Daniele Focosi, Fabrizio Maggi, Massimo Franchini, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 12
Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection
Antonio Vitiello, Francesco Ferrara
Naunyn-Schmiedeberg s Archives of Pharmacology (2021) Vol. 395, Iss. 1, pp. 99-104
Open Access | Times Cited: 11
Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir
Laura J. Stevens, Andrea J. Pruijssers, Hery W. Lee, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication
S. Das, Sreyashi Nath, Shahjahan, et al.
DARU Journal of Pharmaceutical Sciences (2024) Vol. 32, Iss. 2, pp. 801-823
Closed Access
The problem of SARS-CoV-2 virus resistance to direct-acting antivirals
Е. Л. Гасич, Е. Н. Кроткова, A. D. Kasko, et al.
Biological Products Prevention Diagnosis Treatment (2024)
Open Access
Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?
Jessica M. Conway, Pia Abel zur Wiesch
Pharmaceutics (2021) Vol. 13, Iss. 8, pp. 1181-1181
Open Access | Times Cited: 4
Potential and action mechanism of favipiravir as an antiviral against Junin virus
Vahid R. Zadeh, Shuzo Urata, Tosin Oladipo Afowowe, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 1
Remdesivir to treat COVID-19: can dosing be optimized?
Jessica M. Conway, Pia Abel zur Wiesch
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 and a variant of concern in ferrets
Richard K. Plemper, Robert M. Cox, Josef D. Wolf, et al.
Research Square (Research Square) (2021)
Open Access
Page 1

Scroll to top